Utah’s business landscape is rich with professionals who have le...Read More
Social Media and Employers: Friends or Enemies?
The Case for HSAs
Time to Show Up
Make a Move
In the Lab
Rent to Own
Back from the Dead
A Breath of Fresh Air
Travel & Tourism
Salt Lake City – BioFire Diagnostics, LLC, bioMérieux’s molecular biology affiliate, has commenced clinical and analytical studies to evaluate the company’s FilmArray meningitis/encephalitis (ME) panel, with plans to seek both FDA clearance and CE IVD marking.
Infection of the meninges surrounding the brain and spinal cord (meningitis), or of the brain (encephalitis) can have high mortality and morbidity rates depending on the source of infection. Acute bacterial meningitis is a rare, but potentially fatal disease. Conversely, viral meningitis is more common, but typically mild and non-lethal. However, clinical diagnosis of the meningitis syndrome is difficult since their signs and symptoms are virtually indistinguishable. With a run time of about an hour, the comprehensive ME panel requires only 200 microliters of cerebrospinal fluid to test simultaneously for 16 different bacterial, viral, and fungal pathogens known to cause community-acquired meningitis and encephalitis.
“The commencement of studies to evaluate our meningitis test is exciting since the FilmArray has the potential to make a profound impact on treating this fatal disease, where symptoms can appear suddenly and escalate quickly,” said Randy Rasmussen, bioMérieux Corporate vice president of molecular biology and CEO of BioFire Diagnostics.
The clinical study is being conducted at several hospital-based clinical laboratories in the U.S. BioFire expects the FDA submission in 2015. The ME panel will be the fourth clinical diagnostic test to run on the FilmArray System.
Additionally, BioFire will exhibit the FilmArray at booth 1257 during the 2014 American Association of Clinical Chemistry (AACC) annual meeting July 29-31 in Chicago.